Systematic Review and Meta-analysis of Teneligliptin for Treatment of Type 2 Diabetes

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2023 Jan 9

PMID 36624224

Authors

R Pelluri

S Kongara

V R Nagasubramanian

S Mahadevan

J Chimakurthy

Affiliations

Soon will be listed here.

Abstract

Background And Aim: There are efficacy and safety concerns related to teneligliptin treatment. A systematic review of randomized controlled trials (RCTs) was undertaken to comprehensively profile the efficacy and safety of teneligliptin in the treatment of type 2 diabetes mellitus (T2DM).

Methods: Thirteen studies were chosen from a search of scientific databases for RCTs using teneligliptin as a monotherapy or as an adjunct to other glycemic agents with pre-specified inclusion criteria. We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) in each included trial and pooled the data using a random-effects model.

Results: Thirteen studies enrolled 2853 patients were identified. Teneligliptin treatment was associated with weight gain (vs. placebo, weighted mean difference (WMD) 0.28 kg; 95% CI - 0.20-0.77 kg; I = 86%; P = 0.25). Compared to monotherapy, add on therapy with teneligliptin showed significant improvement in FPG mg/dl levels (WMD - 16.75 mg/dl; 95% CI - 19.38 to - 14.13 mg/dl), HOMA-β (WMD 7.91; 95% CI 5.38-10.45) and HOMA-IR (WMD - 0.27; 95% CI - 0.46 to - 0.07). The improvement in HbA1c was greater with monotherapy (WMD - 8.88 mmol/mol; 95% CI - 9.59 to - 8.08 mmol/mol). There was no significant risk of any hypoglycemia with teneligliptin compared to placebo (OR 0.84; 95% CI 0.44-1.60; I = 0%; P = 0.60). However, the risk was 1.84 times high when combined with other glycemic agents. The risk of cardiovascular events was comparable, regardless of treatment duration when compared to placebo or any other active comparator (OR 0.79; 95% CI 0.40-1.57; I = 0%; P = 0.50). [PROSPERO, CRD42022360785].

Conclusions: Teneligliptin is an effective and safe therapeutic option for patients with T2DM, both as monotherapy and as add-on therapy. However, additional large-scale, high-quality, long-term follow-up clinical trials with diverse ethnic populations are required to confirm its long-term efficacy and safety.

Citing Articles

Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome.

Zhang G, Liu Y, Liu Y, Huang X, Tao Y, Chen Z World J Diabetes. 2024; 15(4):724-734.

PMID: 38680706 PMC: 11045420. DOI: 10.4239/wjd.v15.i4.724.

Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis.

Zhu M, Guan R, Ma G Front Endocrinol (Lausanne). 2024; 14:1282584.

PMID: 38189048 PMC: 10766708. DOI: 10.3389/fendo.2023.1282584.

Teneligliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice.

Wang W, Zhang J Aging (Albany NY). 2023; 16(9):8336-8347.

PMID: 38127000 PMC: 11131981. DOI: 10.18632/aging.205333.

References

Nauck M, Meier J . Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018; 20 Suppl 1:5-21. DOI: 10.1111/dom.13129. View

Gupta R, Walunj S, Tokala R, Parsa K, Singh S, Pal M . Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009; 10(1):71-87. DOI: 10.2174/138945009787122860. View

Gorrell M, Gysbers V, McCaughan G . CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001; 54(3):249-64. DOI: 10.1046/j.1365-3083.2001.00984.x. View

Green B, Flatt P, Bailey C . Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006; 3(3):159-65. DOI: 10.3132/dvdr.2006.024. View

Omar B, Ahren B . Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014; 63(7):2196-202. DOI: 10.2337/db14-0052. View

Bohannon N . Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med. 2009; 121(1):40-5. DOI: 10.3810/pgm.2009.01.1953. View

Dutta D, Jindal R, Mehta D, Kumar M, Sharma M . Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis. J Postgrad Med. 2022; 68(2):85-92. PMC: 9196294. DOI: 10.4103/jpgm.JPGM_301_21. View

Drucker D . Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2003; 12(1):87-100. DOI: 10.1517/13543784.12.1.87. View

Holst J . Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006; 49(2):253-60. DOI: 10.1007/s00125-005-0107-1. View

10.

Thornberry N, Gallwitz B . Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009; 23(4):479-86. DOI: 10.1016/j.beem.2009.03.004. View

11.

Seino Y, Kuwata H, Yabe D . Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. J Diabetes Investig. 2016; 7 Suppl 1:102-9. PMC: 4854513. DOI: 10.1111/jdi.12490. View

12.

Garber A . Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011; 34 Suppl 2:S258-63. PMC: 3632189. DOI: 10.2337/dc11-s230. View

13.

Gupta D, Kono T, Evans-Molina C . The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab. 2010; 12(12):1036-47. PMC: 3764483. DOI: 10.1111/j.1463-1326.2010.01299.x. View

14.

Rahier J, Guiot Y, Goebbels R, Sempoux C, Henquin J . Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008; 10 Suppl 4:32-42. DOI: 10.1111/j.1463-1326.2008.00969.x. View

15.

Morishita R, Nakagami H . Teneligliptin : expectations for its pleiotropic action. Expert Opin Pharmacother. 2015; 16(3):417-26. DOI: 10.1517/14656566.2015.1000301. View

16.

Ko S, Hur K, Rhee S, Kim N, Moon M, Park S . Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. Diabetes Metab J. 2017; 41(5):337-348. PMC: 5663672. DOI: 10.4093/dmj.2017.41.5.337. View

17.

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

18.

Sweeting M, Sutton A, Lambert P . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004; 23(9):1351-75. DOI: 10.1002/sim.1761. View

19.

Ji L, Ma J, Lu W, Liu J, Zeng J, Yang J . Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. J Diabetes Investig. 2020; 12(4):537-545. PMC: 8015819. DOI: 10.1111/jdi.13389. View

20.

Agarwal P, Jindal C, Sapakal V . Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study. Indian J Endocrinol Metab. 2018; 22(1):41-46. PMC: 5838908. DOI: 10.4103/ijem.IJEM_97_16. View